FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Tompkins Tamara (Last) (First) (Middle)					2. Issuer Name and Ticker or Trading Symbol Unity Biotechnology, Inc. [UBX] 5. Relationship of Reporting Person(s) to Issue (Check all applicable) Director 10% Owner X Officer (give title Other (specially below)) 3. Date of Earliest Transaction (Month/Day/Year) See Remarks							vner									
C/O UNITY BIOTECHNOLOGY, INC.				03/	03/30/2020																
285 EAST GRAND AVENUE														_							
(Street) SOUTH SAN FRANCISCO CA 94080					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(S	tate)	(Zip)																		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)					es ally Following	Form (D) or	. Ownership orm: Direct O) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership					
									Code	v	Amount	(A) or (D)		Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)		
Common Stock, \$0.0001 par value 03/30/					/2020	/2020 A		24,255	55 ⁽¹⁾ A \$		\$0.00	45,330 ⁽²⁾			D						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, T	4. Transactio Code (Insti				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
				Code V (A) (D) Exercisable Expiration Date Expiration Date Title Shares																	
Stock Option (Right to Buy)	\$5.95	03/30/2020			A		98,490		(3)		03/29/2030	Common Stock	98	3,490	\$0.00	98,490		D			

Explanation of Responses:

- 1. Represents Restricted Stock Units ("RSUs") which vest in equal annual installments over a three year period measured from March 30, 2020. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
- 2. Includes RSUs which vest over time measured from the grant date.
- 3. Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on March 30, 2020 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Remarks:

Corporate Secretary and General Counsel

/s/ Tamara L. Tompkins 04/01/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.